Literature DB >> 6418254

Tyramine-induced noradrenaline release from rat brain slices: prevention by (-)-deprenyl.

V Glover, C J Pycock, M Sandler.   

Abstract

Clorgyline (1 and 10 microM) and (+)-deprenyl (10 microM) both significantly potentiated the tyramine (100 microM)-induced release of [3H]-noradrenaline from rat cerebral cortex slices. (-)-Deprenyl (50 microM) significantly reduced it, while lower concentrations had no effect on noradrenaline release. However, in combination, 1 microM (-)-deprenyl blocked the release-facilitating action of 1 microM clorgyline, and 10 microM (-)-deprenyl that of 10 microM (+)-deprenyl. Low concentrations of (+)- and (-)-deprenyl (1 and 10 microM), both selectively inhibited phenylethylamine oxidation by monoamine oxidase B. Higher concentrations of (-)-deprenyl (20 and 50 microM) also inhibited 5-hydroxytryptamine oxidation by monoamine oxidase A. Clorgyline (1 and 10 microM) inhibited both enzymes. Thus, the effects of these drugs on noradrenaline-release cannot be explained solely in terms of irreversible inhibition of monoamine oxidase A and B, and other possible mechanisms are discussed. If the brain-slice model faithfully mirrors the sequence of events manifesting peripherally as the tyramine hypertensive response ('cheese effect'), then it is possible that low doses of (-)-deprenyl, administered with antidepressant monoamine oxidase inhibitors, can prevent this adverse reaction.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6418254      PMCID: PMC2044979          DOI: 10.1111/j.1476-5381.1983.tb11059.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species.

Authors:  R F Squires
Journal:  Adv Biochem Psychopharmacol       Date:  1972

2.  Some puzzling pharmacological effects of monoamine oxidase inhibitors.

Authors:  J Knoll; K Magyar
Journal:  Adv Biochem Psychopharmacol       Date:  1972

3.  Evidence that deprenyl, A type B monoamine oxidase inhibitor, is an indirectly acting sympathomimetic amine.

Authors:  L L Simpson
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

4.  The effect of some putative neurotransmitters on the release of 5-hydroxytryptamine and gamma-aminobutyric acid from slices of the rat midbrain raphe area.

Authors:  R W Kerwin; C J Pycock
Journal:  Neuroscience       Date:  1979       Impact factor: 3.590

5.  Deprenyl is metabolized to methamphetamine and amphetamine in man.

Authors:  G P Reynolds; J D Elsworth; K Blau; M Sandler; A J Lees; G M Stern
Journal:  Br J Clin Pharmacol       Date:  1978-12       Impact factor: 4.335

6.  The possible mechanisms of action of (-)deprenyl in Parkinson's disease.

Authors:  J Knoll
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

7.  In vivo monoamine oxidase inhibition by d-amphetamine.

Authors:  H H Miller; P A Shore; D E Clarke
Journal:  Biochem Pharmacol       Date:  1980-05-15       Impact factor: 5.858

8.  Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor.

Authors:  M H Lader; G Sakalis; M Tansella
Journal:  Psychopharmacologia       Date:  1970-08-19

9.  Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'.

Authors:  J D Elsworth; V Glover; G P Reynolds; M Sandler; A J Lees; P Phuapradit; K M Shaw; G M Stern; P Kumar
Journal:  Psychopharmacology (Berl)       Date:  1978-04-14       Impact factor: 4.530

10.  Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation.

Authors:  S Lipper; D L Murphy; S Slater; M S Buchsbaum
Journal:  Psychopharmacology (Berl)       Date:  1979-04-11       Impact factor: 4.530

View more
  5 in total

1.  Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat.

Authors:  J P Finberg; M B Youdim
Journal:  Br J Pharmacol       Date:  1985-06       Impact factor: 8.739

2.  Tyramine pressor sensitivity changes during deprenyl treatment.

Authors:  T Sunderland; E A Mueller; R M Cohen; D C Jimerson; D Pickar; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

3.  The neuropharmacological profile of N-methyl-N-propargyl-2-aminotetralin: a potent monoamine oxidase inhibitor.

Authors:  B Hazelhoff; J B De Vries; D Dijkstra; W de Jong; A S Horn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-07       Impact factor: 3.000

Review 4.  Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.

Authors:  E H Heinonen; V Myllylä
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

5.  Sympathetic nerve-derived ATP regulates renal medullary vasa recta diameter via pericyte cells: a role for regulating medullary blood flow?

Authors:  C Crawford; S S P Wildman; M C Kelly; T M Kennedy-Lydon; C M Peppiatt-Wildman
Journal:  Front Physiol       Date:  2013-10-29       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.